2024-06-27 10:30
The purpose of the extra general meeting that Biovica has called for on July 15, 2024, is to decide on share-based incentive programs for employees and the board of Biovica International AB and subsidiaries. By doing so at an extraordinary general meeting...
2022-12-01 14:40
Biovica, active in cancer diagnostics, today announces that the company has employed a sales team of total of eight people to secure a fast and smooth launch and the further commercial development of DiviTum® TKa on the US market.
2022-11-22 14:55
Biovica, active in cancer monitoring, today announces that the unique study design of the TK IMPACT trial, using the DiviTum® TKa blood test, will be presented as a poster at the world’s largest breast cancer symposium, SABCS, on December 8.
2022-11-22 14:50
Biovica, active in cancer monitoring, today announces that results from a study using the DiviTum® TKa blood test will be presented at the world’s largest breast cancer symposium, SABCS, on December 8. The results support using DiviTum® TKa to predict...
2021-04-23 08:30
Biovica, active in cancer diagnostics, today announced that the results from a budget impact model of monitoring with DiviTum®TKa can give savings of up to three times the extra spend relative to current management. The results will be presented at the...
2021-01-18 08:00
DiviTum®TKa has been selected to be included in the new prospective clinical study TIRESIAS, with the aim of investigating if DiviTum®TKa can be used to identify early resistance to treatment by a CDK4/6 inhibitor in combination with an aromatase inhibitor...
2021-01-12 11:50
Biovica's CEO and main shareholder Anders Rylander has, to facilitate the administration of the company's warrant program 3, lent 127,000 shares to Pareto Securities AB.
2020-11-23 08:00
DiviTum®TKa has been selected to be included in a new prospective study of women with hormone receptor positive metastatic breast cancer. The aim of including DiviTum®TKa in the study is to investigate if this marker can be used for disease monitoring...
2020-11-20 08:00
Biovica, active in cancer diagnostics, today announced that positive DiviTum®TKa results from the European multicenter study PYTHIA will be presented at the world´s leading breast cancer conference, SABCS, in early December.
2020-11-19 08:00
Biovica, active in cancer diagnostics, today announced that positive DiviTum®TKa results from a clinical study at the University of Nebraska Medical Center and Washington University School of Medicine, US, will be presented at the world´s leading breast...
>4,500
Numbers of patients in studies
28
Publications
32
Pharma Projects